[Risks, benefits and costs of hormone replacement therapy in menopause].
Hormone replacement therapy (HRT) acts both as an effective treatment of menopausal symptoms and genital atrophy, and as an effective prevention of osteoporosis. It is also probably cardioprotective and potentially preventing cerebrovascular disease. The risk of oestrogen-induced endometrial cancer is eliminated by the addition of a progestin. An increase in breast cancer risk is however possible after 10 years or more of HRT use. This multifactorial risk-benefit balance altogether with other variables (numerous and expensive hormonal therapies, low compliance of postmenopausal women, need for monitoring, therapy-related adverse events) explain why so few global pharmaco-economic appraisals have been devoted to HRT. Computer model studies have been set up to study hypothetical cohorts of menopausal women treated for 5-10 years or more, comprising hysterectomized women (receiving an estrogen alone) and non hysterectomized women (receiving an oestrogen-progestogen therapy) compared with untreated controls. Treatment of hysterectomized women as well as non hysterectomized symptomatic menopausal women appears relatively cost-effective. In terms of mortality and morbidity, a reduction in cardiovascular disease risk and, to a smaller extent, in osteoporosis has a strikingly greater impact than the small increase in breast cancer risk related to HRT use. A significant increase in life expectancy seems associated with long-term use and the quality-adjusted life years gain, is particularly impressive, as quality of life appears distinctly improved by HRT utilization. In the future, this beneficial cost-effectiveness equation will probably be optimized thanks to the introduction of alternative and innovative replacement therapies allowing longer treatment periods without increasing the risk of breast cancer.
Gaspard
U
U
Service deGynécologie, Université de Liège.
D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000139:chemically induced / Q000191:economics; D002561:Cerebrovascular Disorders / Q000191:economics / Q000517:prevention & control; D015331:Cohort Studies; D003198:Computer Simulation; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D016527:Drug Costs; D016903:Drug Monitoring / Q000191:economics; D017850:Economics, Pharmaceutical; D016889:Endometrial Neoplasms / Q000139:chemically induced / Q000191:economics; D015914:Estrogen Replacement Therapy / Q000009:adverse effects / Q000191:economics*; D004967:Estrogens / Q000009:adverse effects; D005260:Female; D006331:Heart Diseases / Q000191:economics / Q000517:prevention & control; D006801:Humans; D007044:Hysterectomy; D008017:Life Expectancy; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D008954:Models, Biological; D015663:Osteoporosis, Postmenopausal / Q000191:economics / Q000517:prevention & control; D010349:Patient Compliance; D011372:Progestins / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D018570:Risk Assessment
D004967:Estrogens; D011372:Progestins